Stock Price & Analysis

Based on the analysis of PYXS stock, here is a concise recommendation:

Buy PYXS as it has strong analyst support and promising clinical developments with FDA Fast Track Designation. Sell PYXS if you prefer lower-risk investments due to its high volatility and cash burn concerns.

The price prediction for PYXS stock in 2025 is expected to reach $1.27 in the short term and $8.00 in the long term, driven by positive analyst ratings and FDA Fast Track Designation for its lead candidate.

The S1 support level for PYXS Stock is $0.95 ,The R1 resistant level for PYXS Stock is $1.21.

As of the end of day on 2025-04-01, the price of PYXS Stock was $0.964.

The target price for PYXS Stock according to analyst rating is 7.25, with the highest price target at 10.00 and the lowest at 5.00. Analysts have a Strong Buy rating on PYXS Stock overall.

The market cap of PYXS is $56.4M.

Analysis and Insights

PYXS appears overvalued based on its financial performance and market valuation. Here's the analysis:

1. Lack of Revenue Growth: PYXS has not generated significant revenue, with only $16.1 million reported in Q1 2024 and no revenue in subsequent quarters, raising concerns about its ability to sustain operations.

2. High Cash Burn: The company is burning through $54 million annually, which is 71% of its market capitalization. This high burn rate indicates a significant risk of shareholder dilution if additional funding is required.

3. Negative Earnings: PYXS has reported consistent net losses, with negative EPS in all quarters of 2024. This indicates the company is not yet profitable and may struggle to achieve positive earnings in the near term.

4. Volatility: The stock has shown significant price swings, with a 24% intraday high and a -1.66% post-market drop, highlighting the risks of investing in such a volatile stock.

5. Mixed Analyst Sentiment: While some analysts maintain a buy rating with a target of $8, others have a hold rating, reflecting uncertainty about the stock's future performance.

Conclusion

Given the lack of revenue, high cash burn, and negative earnings, PYXS appears overvalued. Investors should exercise caution and consider these risks before making any investment decisions.

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

The price prediction for PYXS stock by 2030 is estimated to reach $5 to $10 per share, driven by its strong growth momentum and positive market performance. Current trends indicate significant upside potential.

PYXS has a total of 50 employees.